<DOC>
	<DOC>NCT02766439</DOC>
	<brief_summary>between March 2013 and March 2014, Rhupus patients were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.</brief_summary>
	<brief_title>Rhupus Syndrome and Efficacy of Etanercept Treatment</brief_title>
	<detailed_description>between March 2013 and March 2014, patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) &gt;5.1 were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Rhupus patients who were unresponsive to therapy with corticosteroid and diseasemodifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) &gt;5.1 those who had participated in other studies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>